The global Radiopharmaceuticals/Nuclear
Medicine Market size
is expected to reach USD 15.2 billion by 2025, according to a new report by
Grand View Research, Inc., registering a 10.1% CAGR during the forecast period.
The burden of chronic diseases such as cancer and cardiac disorders is on a
rise. Nuclear medicine is widely used for diagnosis as well as treatment of
such disorders.
Increasing prevalence of these disorders
has a direct impact on usage of radiopharmaceuticals. As per data published by
the World Health Organization (WHO), cancer is the second leading cause of
death around the globe and in 2015, accounted for 8.8 million deaths. This is
anticipated to drive demand for radiopharmaceuticals in the years to come.
Diagnostics, when combined with nuclear
medicine, improve accuracy to a great extent. This can have a direct impact on
decision-making and treatment monitoring processes. Adoption of PET as a
diagnostic tool is rapidly increasing since it has shown greater precision over
other diagnostic techniques.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/nuclear-medicines-market
Further key
findings from the report suggest:
- By product, the nuclear medicine market was dominated by the
diagnostic segment in 2015, driven primarily by advancements in scanning
technologies
- The therapeutic segment, which comprises alpha emitters, beta
emitters, and brachytherapy, is anticipated to exhibit lucrative growth
over the coming years
- On the basis of application, diagnostic formed the largest segment
in 2015, including key areas such as cardiology, neurology, oncology, and
thyroid
- North America dominated the global radiopharmaceuticals market in
2015 owing to well-planned policies, favorable reimbursement structure,
high healthcare spending, and increasing awareness
- Asia Pacific is expected to witness lucrative growth in the coming
years. Increasing per capita income and reform in policies is attracting
market players
- Key players in the industry include Eckert & Ziegler Group;
Mallinckrodt Pharmaceuticals; GE Healthcare; Jubilant Life Sciences;
Bracco Imaging S.p.A; and Nordion, Inc.
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment